Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Cambrex Corporation    CBM

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/12/2017 01/13/2017 01/17/2017 01/18/2017 01/19/2017 Date
55.2(c) 55.85(c) 54.05(c) 54.75(c) 54(c) Last
152 039 162 663 154 390 123 156 164 039 Volume
-1.60% +1.18% -3.22% +1.30% -1.37% Change
More quotes
Financials ($)
Sales 2016 487 M
EBIT 2016 123 M
Net income 2016 82,6 M
Debt 2016 -
Yield 2016 -
Sales 2017 543 M
EBIT 2017 141 M
Net income 2017 91,7 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 21,51
P/E ratio 2017 19,53
Capi. / Sales2016 3,57x
Capi. / Sales2017 3,20x
Capitalization 1 736 M
More Financials
Company
Cambrex Corp. engages in the provisio ofproducts, services and technologies to accelerate and improve the development and commercialization of new and generic therapeutics.It supplies its products and services to innovator and generic pharmaceutical companies.Its products include generic and... 
Sector
Pharmaceuticals
Calendar
02/14Earnings Release
More about the company
Surperformance© ratings of Cambrex Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CAMBREX CORPORATION
01/05 CAMBREX : Talks continue on site for North Haven train station
01/05 CAMBREX : Appoints Tom Vadaketh as Executive Vice President and Chief Financial ..
01/05 CAMBREX : Appoints Tom Vadaketh as Executive Vice President and Chief Financial ..
01/04 CAMBREX : Appoints Tom Vadaketh as Executive Vice President and Chief Financial ..
01/04 CAMBREX CORPORATION (NYSE : CBM) Files An 8-K Departure of Directors or Certain ..
01/04 CAMBREX CORP : Change in Directors or Principal Officers (form 8-K)
01/04 Cambrex Appoints Tom Vadaketh as Executive Vice President and Chief Financial..
01/04 CAMBREX : Talks continue on site for North Haven train station
2016 CAMBREX : Earnings slide
2016 CAMBREX : posts 3Q profit
More news
Sector news : Pharmaceuticals - NEC
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
01/19 GSK grabs Astra executive to replace pharma head
01/19DJGLAXOSMITHKLINE : Global Pharmaceuticals President Abbas Hussain to Leave -- Upd..
More sector news : Pharmaceuticals - NEC
Latest Tweets
01/17Cambrex Corporation's PT raised by First Analysis to $66.00. overweight ratin.. 
01/10Cambrex Corporation downgraded by Zacks Investment Research to hold.  
01/09Here are 7 stocks with room to grow! $CBM $MDR $AMAT $COHR $LMCA $TLRD $KE  
01/04$CBM: Cambrex appoints Tom Vadaketh as CFO effective Jan 20, 2017; current CF.. 
01/04BRIEF-Cambrex appoints Tom Vadaketh as chief financial officer  
More tweets
Qtime:55
News from SeekingAlpha
2016 Cambrex's (CBM) CEO Steve Klosk on Q3 2016 Results - Earnings Call Transcript
2016 Cambrex revenues up 7%; non-GAAP EPS up 18% in Q3; revises 2016 guidance
2016 Cambrex beats by $0.06, beats on revenue
2016 Notable earnings before Friday?s open
2016 CAMBREX : Overblown Concerns Present Attractive Entry Opportunity Into Growing M..
Advertisement
Chart CAMBREX CORPORATION
Duration : Period :
Cambrex Corporation Technical Analysis Chart | CBM | US1320111073 | 4-Traders
Full-screen chart
Technical analysis trends CAMBREX CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 52,0 $
Spread / Average Target -3,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Steven M. Klosk President, Chief Executive Officer & Director
Shlomo Yanai Non-Executive Chairman
Shawn P. Cavanagh Chief Operating Officer & Executive Vice President
Gregory P. Sargen Chief Financial Officer & Executive Vice President
Peter G. Tombros Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CAMBREX CORPORATION0.09%1 736
JOHNSON & JOHNSON-0.88%310 685
ROCHE HOLDING LTD.1.29%200 208
PFIZER INC.-2.40%192 367
NOVARTIS AG-3.71%185 489
MERCK & CO., INC.2.48%166 338
More Results